 |
인쇄하기
취소
|
New homegrown antimalarial drug to be approved in first half
The Korea Food and Drug Administration is likely to approve Pyramax, an investigational antimalarial medicine developed by Shinpoong Pharmaceutical Co, possibly in the first half of this year.
Pyramax is a fixed-dose combination of pyronaridine and artesunate that has completed a program of clinical trials demonstrating more than 95% efficacy at day 28.
“We may be able to approve Pyramax ...
Pyramax is a fixed-dose combination of pyronaridine and artesunate that has completed a program of clinical trials demonstrating more than 95% efficacy at day 28.
“We may be able to approve Pyramax ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.